This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thorne, S. A. Articles by Somerville, J. Search for Related Content PubMed PubMed Citation Articles by Thorne, S. A. Articles by Somerville, J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMIODARONE HYDROCHLORIDE Medline Plus Health Information Congenital Heart Defects Thyroid Diseases Related Collections Cardiovascular Pharmacology Pediatric and congenital heart disease, including cardiovascular surgery Arrhythmias, clinical electrophysiology, drugs

(Circulation. 1999;100:149-154.)
© 1999 American Heart Association, Inc.

Clinical Investigation and Reports

Amiodarone-Associated Thyroid Dysfunction

Risk Factors in Adults With Congenital Heart Disease

Sara A. Thorne, MD, MRCP; Isobel Barnes, MSc; Paul Cullinan, MD; Jane Somerville, MD, FRCP, FESC

From the Grown-Up Congenital Heart Disease Unit, Royal Brompton Hospital (S.A.T., J.S.), and the Department of Occupational and Environmental Medicine, Imperial College of Science, Technology, and Medicine (I.B., P.C.), London, UK.

Correspondence to Dr S.A. Thorne, Royal Brompton Hospital, Sydney St, London SW3 6NP, UK. E-mail s.thorne{at}rbh.nthames.nhs.uk

Background—Amiodarone is widely used in adults with congenital heart disease, but no systematic study has been published on its effects on thyroid function in these patients. A retrospective study was performed to examine the frequency of amiodarone-associated thyroid dysfunction in adults with congenital heart disease and to identify any contributing factors.

Methods and Results—All adults (16 to 60 years old) with congenital heart disease were identified from a database if they had no preexisting thyroid disease, had taken amiodarone for 6 months, and were currently followed up by 1 consultant (J.S.). Ninety-two patients were found and evaluated for thyroid status and cardiac complications. A case-control analysis was performed, with patients matched for duration of amiodarone therapy. Of the 92 patients (age, 34.9±10.2 years; range, 18 to 60 years), 36% developed thyroid dysfunction: 19 became hyperthyroid and 14 hypothyroid. Female sex and complex cyanotic heart disease were significant risk factors for developing thyroid dysfunction (odds ratios, 3.0 and 7.00; P=0.04 and 0.01, respectively). Previous Fontan-type surgery also appeared to be a risk factor for developing thyrotoxicosis (odds ratio, 4.0; P=0.17), and amiodarone >200 mg/d a risk factor for thyroid dysfunction (odds ratio, 4.0; P=0.60).

Conclusions—Amiodarone-associated thyroid dysfunction is common in adults with congenital heart disease. Women and those with complex cyanotic lesions are at particular risk, as patients may be who have had Fontan-type surgery or are taking >200 mg/d of amiodarone. Amiodarone should be used only when other antiarrhythmics are ineffective or contraindicated. Vigilance is required to detect and treat thyroid dysfunction.

Key Words: heart defects, congenital • amiodarone • thyroid

This article has been cited by other articles:

				Y.-L. Liang, S.-M. Huang, S.-L. Peng, S.-H. Hsiao, H.-C. Hung, H.-Y. Ou, and T.-J. Wu Amiodarone-Induced Thyrotoxicosis in a Patient with Autonomously Functioning Nodular Goiter Ann. Pharmacother., January 1, 2009; 43(1): 134 - 138. [Abstract] [Full Text] [PDF]

				The Task Force on the Management of Grown Up Conge, Task Force members, J. Deanfield, E. Thaulow, C. Warnes, G. Webb, F. Kolbel, A. Hoffman, K. Sorenson, H. Kaemmerer, et al. Management of Grown Up Congenital Heart Disease Eur. Heart J., June 1, 2003; 24(11): 1035 - 1084. [Full Text] [PDF]

				E. Martino, L. Bartalena, F. Bogazzi, and L. E. Braverman The Effects of Amiodarone on the Thyroid Endocr. Rev., April 1, 2001; 22(2): 240 - 254. [Abstract] [Full Text]